Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-09-16

Clinical Trial Update: Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing pembrolizumab to topotecan in small cell lung cancer was terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pembrolizumab (pembrolizumab)
  • Topotecan (topotecan)

Snippet

Sponsor: Alliance Foundation Trials, LLC. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-09-16